A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
Northwestern University
Stanford University
University of Nebraska
University of Nebraska
University of Nebraska
City of Hope Medical Center
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Mayo Clinic
M.D. Anderson Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
University of Chicago
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Mayo Clinic
Alliance for Clinical Trials in Oncology
Columbia University
Ohio State University Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
University of South Florida
Northside Hospital, Inc.
Vanderbilt-Ingram Cancer Center
Northside Hospital, Inc.
Mayo Clinic